Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks entered an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks receives a $55 million upfront, a $40 million payment upon Phase 1b initiation, and up to $718 million in additional milestones, plus tiered high-single-digit to mid-teen royalties on global net sales. Roche funds the Phase 1a trial and gains exclusive global rights to develop and commercialize ZW209, which has FDA IND clearance for a Phase 1 study in DLL3-expressing tumors including small cell lung cancer.
Key figures
- Deal Value Usd
- $55 million upfront plus up to $718 million in milestones
- Royalties
- tiered high-single-digit to mid-teen on global net sales
- Milestones max
- $718 million
- Upfront payment
- $55 million
- Phase 1b milestone
- $40 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.